Evidence map›Paper›PMID 20566830›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2010

Innate retroviral restriction by Apobec3 promotes antibody affinity maturation in vivo.

Mario L Santiago, Robert L Benitez, Mauricio Montano, Kim J Hasenkrug, Warner C Greene

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Mouse knockout models for HIV-1 restriction factors.Cellular and molecular life sciences : CMLS · 2014
    Review
  13. Immunoglobulin somatic hypermutation by APOBEC3/Rfv3 during retroviral infection.Proceedings of the National Academy of Sciences of the United States of America · 2014
    Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Mario L SantiagoDivision of Infectious Diseases, University of Colorado Denver, Mail Stop B168, 12700 East 19th Avenue, Aurora, CO 80045, USA. mario.santiago@ucdenver.edu
Robert L Benitez
Mauricio Montano
Kim J Hasenkrug
Warner C Greene
Gladstone Institutes · USNational Institute of Allergy and Infectious Diseases · USUniversity of California, San Francisco · USUniversity of Colorado Denver · US

Funding

Immunology And Pathology Of Acute Murine Leukemia Virus InfectionsZIAAI000753 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI HASENKRUG, KIM · 2009 to 2022
$8.1M
Immunology and Pathology of Chronic Murine Leukemia Virus InfectionsZIAAI001100 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI HASENKRUG, KIM · 2009 to 2015
$3.1M
Innate Restriction Factor Modulation of Retrovirus-specific Humoral ImmunityR01AI090795 · NIAID · UNIVERSITY OF COLORADO DENVER · PI SANTIAGO, MARIO LUIS · 2010 to 2013
$2.8M
Regulation and Action of APOBEC3GR01AI065329 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI GREENE, WARNER C. · 2005 to 2009
$1.9M
Apobec3 and the Neutralizing Antibody Response Against Pathogenic RetrovirusesR56AI084123 · NIAID · UNIVERSITY OF COLORADO DENVER · PI SANTIAGO, MARIO LUIS · 2009 to 2009
$658k
Exploring and Exploiting APOBEC3G BiologyR56AI065329 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI GREENE, WARNER C. · 2009 to 2009
$595k
NIAID NIH HHS R01 AI065329NIAID NIH HHS R01 AI090795NIAID NIH HHS R56 AI065329NIAID NIH HHS R56 AI084123NIAID NIH HHS R56 AI-0841230PHS HHS R01 A065329
6 · The paper itself

Abstract

Apobec3/Rfv3 is an innate immune factor that promotes the neutralizing Ab response against Friend retrovirus (FV) in infected mice. Based on its evolutionary relationship to activation-induced deaminase, Apobec3 might directly influence Ab class switching and affinity maturation independently of viral infection. Alternatively, the antiviral activity of Apobec3 may indirectly influence neutralizing Ab responses by reducing early FV-induced pathology in critical immune compartments. To distinguish between these possibilities, we immunized wild-type and Apobec3-deficient C57BL/6 (B6) mice with (4-hydroxy-3-nitrophenyl) acetyl (NP) hapten and evaluated the binding affinity of the resultant NP-specific Abs. These studies revealed similar affinity maturation of NP-specific IgG1 Abs between wild-type and Apobec3-deficient mice in the absence of FV infection. In contrast, hapten-specific Ab affinity maturation was significantly compromised in Apobec3-deficient mice infected with FV. In highly susceptible (B6 x A.BY)F(1) mice, the B6 Apobec3 gene protected multiple cell types in the bone marrow and spleen from acute FV infection, including erythroid, B, T, and myeloid cells. In addition, B6 Apobec3 deficiency was associated with elevated Ig levels, but decreased induction of splenic germinal center B cells and plasmablasts during acute FV infection. These data suggest that Apobec3 indirectly influences FV-specific neutralizing Ab responses by reducing virus-induced immune dysfunction. These findings raise the possibility that enabling Apobec3 activity during acute infection with human pathogenic retroviruses, such as HIV-1, may similarly facilitate stronger virus-specific neutralizing Ab responses.

Indexed as

AnimalsAntibodies, NeutralizingAntibodies, ViralAntibody AffinityBone Marrow CellsCytidine DeaminaseFemaleFlow CytometryFriend murine leukemia virusHumansImmunizationLeukemia, ExperimentalMaleMiceMice, Inbred BALB CMice, Inbred C57BL4-hydroxy-5-nitrophenyl acetic acidAntibodies, NeutralizingAntibodies, ViralApobec3 protein, mouseCytidine DeaminaseNitrophenolsPhenylacetates

Identifiers

PMID20566830
PMCPMC3024598
OpenAlexW2105555705

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.